Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Washington University School of Medicine
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01670877
First received: August 17, 2012
Last updated: October 11, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2020
  Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)